Literature DB >> 11758612

Testing the predictability of the relative urinary supersaturation from the Bonn-Risk-Index for calcium oxalate stone formation.

N Laube1, S Hergarten, A Hesse.   

Abstract

When introducing a new parameter, it is necessary to compare the power of the new measure with already established ones. For a new method it is quite difficult to compete with established methods which have already ascertained sets of data over many years. A formal comparison of the new parameter with the actual "gold-standard" method can be a useful approach to reduce that problem. It cannot be expected that a new measure would reflect the "gold-standard" method in a simple proportionality. Therefore, it is important to find out the accuracy of the prediction of one parameter from the other, based on simple, e.g. linear, functions. A number of methods exist to determine the crystallization risk of calcium oxalate salts from urine. The most established method is the calculation of the relative urinary supersaturations with respect to these salts using the EQUIL-program, a program computing the equilibrium concentrations of complexes of primary cations and anions commonly found in urine. The Bonn-Risk-Index (BRI) is a new strategy for the evaluation of the risk of calcium oxalate formation, by performing crystallization experiments on native unprepared urine samples. Although the analytical and computational efforts of both approaches are quite different (relative supersaturation = high, BRI = low), the measurements revealed a considerable and significant linear relationship between the relative urinary calcium oxalate supersaturation, and BRI. We were, therefore, interested in predicting the relative supersaturation from the BRI and in the accuracy of this prediction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758612     DOI: 10.1515/CCLM.2001.156

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  3 in total

1.  [On the uncertainty of measurements illustrated by the BONN Risk Index].

Authors:  N Laube; L Kleinen
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

2.  [Stone treatment tomorrow and the day after].

Authors:  A Miernik; S Hein; F Adams; J Halbritter; M Schoenthaler
Journal:  Urologe A       Date:  2016-10       Impact factor: 0.639

Review 3.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.